NeuroBlu Analytics v5.0 brings our biggest dataset yet, 26R2 with 46M patients and 5M net new lives since 26R1, across an expanded partner network. This release adds 18+ new scale-by-partner mappings across cognitive, mood, anxiety, AUD, suicide-risk, and motor assessments, ships Reports with Treatment Patterns into Beta availability, expands Symptom Intelligence into anxiety and bipolar disorder, and deepens clinical coverage across both neurological and behavioal health.
‍

‍
26R2 Dataset: 46M Patients, New Partners, Deeper Coverage

The 26R2 dataset adds 5M net new lives, pushing total coverage past 46M patients across an expanded partner network. It includes 18+ new scale-by-partner mappings across cognitive, mood, anxiety, AUD, suicide-risk, and motor assessments, with deeper patient counts across both neurological and behavioral health conditions.

Patient coverage across key neurological conditions now includes:

• Alzheimer's Disease (520K+)
• Mild Cognitive Impairment (428K+)
• Dementia (2.1M+)
• Parkinson's Disease (324K+)
• Epilepsy (829K+)
• ALS (10.8K+)
• Migraine (2.7M+)
• Sleep Disorders (2.1M+)
• Pain Disorders (23.9M+)

Our behavioral health dataset also continues to expand:

• Major Depressive Disorder (12.4M+)
• Substance Use Disorder (10.8M+)
• Generalized Anxiety Disorder (7.0M+)
• Attention Deficit Hyperactivity Disorder (5.4M+)
• Post-Traumatic Stress Disorder (2.4M+)
• Bipolar I Disorder (574K+)
• Bipolar II Disorder (486K+)
• Schizophrenia (541K+)
• Obsessive Compulsive Disorder (490K+)
• Schizoaffective Disorder (436K+)
• Borderline Personality Disorder (272K+)

‍

Reports: Treatment Patterns Now Live

Generate reports from your Cohort Explorer projects in just a few clicks.

Reports launches with Treatment Patterns, giving you a comprehensive view of medication usage within a selected patient cohort. This includes how treatments are sequenced over time, transitions between lines of therapy, adherence levels, and gaps in care. Longitudinal visualizations support the evaluation of real-world persistence, therapeutic effectiveness, and opportunities to optimize clinical pathways.

Run treatment-pattern analyses directly within the platform. Studies that once depended on analyst time can now be executed independently, shortening the path from question to insight.

Reports is available in BETA today.

‍

Expanded Symptom Intelligence: Enhanced Coverage Across 5 Disorders

(symptom_lookup) expands to 3,099 validated mappings across 63 symptoms and 5 disorders, covering schizophrenia, MDD, dementia, anxiety, and bipolar disorder. Mappings are drawn from diagnoses, 7 validated scales, mental status exams, and NLP, surfacing symptom-level detail that claims data cannot see.

Every mapping has been reviewed by a board-certified psychiatrist, ensuring clinical accuracy across every entry.

‍

NeuroBlu now covers 46M patients across an expanded partner network, with 18+ new scale-by-partner mappings, Reports live in BETA, and Symptom Intelligence expanded across validated 5 disorders.

Interested in what's new? Book a demo to see NeuroBlu Analytics v5.0 in action.

‍